Let us build your probiotic solution together
Enter your technical specifications in our project qualification form. Your requirements go straight to our R&D teams, who will then get back to you.

From strain selection through to your finished product, PiLeJe CDMO draws on 30 years of experience in probiotics. A probiotic is a living organism: our whole craft consists in preserving its viability, from the strain through to the date of minimum durability of the final food supplement.
Our approach covers every strategic stage of your development.

Rigorous selection, precise genomic identification and characterisation of probiotic strains.

espoke formulations matched to your health objectives and your target population (capsules, single-layer or bilayer tablets, sachets).

Securing the scale-up and the move to large-scale production, in our high-technology plant.

Packaging plays an essential role, protecting the actives from interactions with an environment that can prove damaging.

Analytical monitoring of bacterial viability, with strict controls.
Our collection, enriched year after year, brings together more than 40 characterised and genetically identified strains across 15 species. We secure the quality and the safety of the microorganisms that go into your products.

The strains selected are safe for human consumption and appear on the QPS (Qualified Presumption of Safety) list drawn up by EFSA.

The potential of a strain can be assessed through specific tests: resistance to digestive conditions (gastroduodenal environment), adhesion to mucous membranes, antimicrobial or immunomodulatory properties.

A probiotic is not an active like any other: it is a living organism, and it has to be preserved through to the final food supplement. Our plant adjusts every production parameter to rule out the factors that cause degradation.
To build value into your products, our teams design high-performance dosage forms, sized to the demands of living strains.

ulti-strain formulation, or synergy between probiotics and complementary actives (vitamins, minerals, plant extracts).

Bilayer tablets to isolate incompatible ingredients or to sequence their release, gastro-resistant capsules to protect the microorganisms from gastric acidity.
Your trials and your industrial production take place in the same location, with no transfer and no interruption. PiLeJe CDMO secures your supply chain in this way, with evidence-based guarantees.

ur group is B Corp certified and committed to a decarbonisation pathway validated by the SBTi (Scopes 1, 2 and 3).

All your microbiome supplements are manufactured in France, at our Saint-Bonnet-de-Rochefort site, certified to the FSSC 22000 standard and operating in accordance with the requirements of the FDA 21 CFR Part 111 framework, with an annual audit carried out by independent third parties.

Enter your technical specifications in our project qualification form. Your requirements go straight to our R&D teams, who will then get back to you.
Once the dosage form has been validated and the pilot trials completed, the average lead time for large-scale manufacturing of a probiotic supplement is around 3 to 4 months, between the firm order and delivery of the batches. This cycle secures compliance with our quality control protocols before the products are released.
Strain characterisation rests first on the scientific documentation provided by our suppliers, which our teams assess during the listing process: identification, safety, and the data available on the behaviour of the strain (resistance to digestive conditions, adhesion to mucous membranes, antimicrobial or immunomodulatory properties depending on the strain). On our side, we verify the genetic identity of the strains and check their viability on every batch.
Yes. Our entire collection of more than 40 characterised and genetically identified strains (15 species) is fully traceable. These strains are recognised as safe for human consumption and listed on the QPS (Qualified Presumption of Safety) list drawn up by EFSA. Their blending is centralised at our Saint-Bonnet-de-Rochefort site, certified to the FSSC 22000 standard and operating in accordance with the requirements of the FDA 21 CFR Part 111 framework.
Yes. We manufacture probiotic formulations for brands targeting markets outside the EU, including dietary supplements intended for the US, where the CFU count declared on the Supplement Facts panel must hold through to the end of shelf life. That is precisely what our production conditions and our batch-by-batch viability checks are built for. One point to keep in mind: the QPS list is an EFSA framework, and strain status is assessed differently in the US. Confirming the status of each strain for the target market, and handling any filings it requires, remains the responsibility of the brand owner. We supply the technical documentation on our strains and processes to support that work.